D.E. Shaw & Co
ODT

D.E. Shaw & Co’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

D.E. Shaw & Co’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-374,195
Closed -$505K – 6234
2021
Q4 		$505K Buy
374,195
+140,855
+60% +$333K ﹤0.01% 4400
2021
Q3 		$679K Sell
233,340
-106,728
-31% -$355K ﹤0.01% 3887
2021
Q2 		$1.19M Buy
340,068
+39,236
+13% +$135K ﹤0.01% 3401
2021
Q1 		$1.03M Buy
300,832
+149,732
+99% +$2.83M ﹤0.01% 3086
2020
Q4 		$2.9M Buy
151,100
+48,647
+47% +$751K ﹤0.01% 2302
2020
Q3 		$1.38M Buy
102,453
+1,378
+1% +$39K ﹤0.01% 2648
2020
Q2 		$4.28M Buy
101,075
+368
+0.4% +$11.9K 0.01% 1766
2020
Q1 		$2.78M Sell
100,707
-11,290
-10% -$329K ﹤0.01% 1908
2019
Q4 		$3.63M Buy
111,997
+41,913
+60% +$1.3M ﹤0.01% 1996
2019
Q3 		$1.82M Buy
+70,084
New +$2.35M ﹤0.01% 2424
2018
Q4 		– Sell
-18,359
Closed -$356K – 4091
2018
Q3 		$356K Sell
18,359
-2,423
-12% -$49.4K ﹤0.01% 3292
2018
Q2 		$459K Sell
20,782
-15,409
-43% -$359K ﹤0.01% 3169
2018
Q1 		$767K Buy
+36,191
New +$854K ﹤0.01% 2667

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

D.E. Shaw & Co's ODT Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 374,195 shares — an estimated $505K sold.

D.E. Shaw & Co first reported a position in ODT in Q1 2018 and held it in 13 quarters. The position peaked at $4.28M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 374,195 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $505K.
  • D.E. Shaw & Co first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
  • D.E. Shaw & Co's Odonate Therapeutics, Inc. Common Stock position peaked at $4.28M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.